Reaction
Enteritis Infectious reporting signals
As of the last recalculation, Enteritis Infectious appears in 1,680 FAERS reports alongside 34 co-occurring drug terms. The strongest observed disproportionality signal is AZACITIDINE (PRR 12.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Azacitidine | 29 | 12.3 | 12.3 |
| Granisetron Hydrochloride | 9 | 10.7 | 10.7 |
| Hydrocortisone Sodium Succinate | 8 | 10.6 | 10.6 |
| Lubiprostone | 8 | 10.5 | 10.5 |
| Micafungin Sodium | 7 | 10.3 | 10.3 |
| Piperacillin Sodium And Tazobactam Sodium | 15 | 9.5 | 9.6 |
| Febuxostat Tablets 40 Mg | 7 | 8.6 | 8.6 |
| Febuxostat Tablets 80 Mg | 7 | 8.6 | 8.6 |
| Canakinumab | 7 | 8.0 | 8.0 |
| Pitavastatin Calcium | 6 | 7.3 | 7.3 |
| Selexipag | 15 | 7.2 | 7.3 |
| Suvorexant | 7 | 6.7 | 6.7 |
| Vedolizumab | 39 | 5.7 | 5.7 |
| Levocetirizine Dihydrochloride | 11 | 5.7 | 5.7 |
| Lapatinib | 7 | 5.6 | 5.6 |
| Teduglutide | 6 | 5.5 | 5.5 |
| Tolvaptan | 6 | 5.1 | 5.1 |
| Encorafenib | 4 | 5.0 | 5.0 |
| Certolizumab Pegol | 46 | 5.0 | 5.0 |
| Brentuximab Vedotin | 4 | 4.8 | 4.8 |
| Ravulizumab | 5 | 4.6 | 4.6 |
| Cetuximab | 11 | 4.4 | 4.4 |
| Ipilimumab | 15 | 4.3 | 4.3 |
| Belimumab | 11 | 4.3 | 4.3 |
| Ambrisentan | 42 | 4.2 | 4.2 |
| Ixazomib | 9 | 3.9 | 3.9 |
| Axicabtagene Ciloleucel | 3 | 3.8 | 3.8 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 3.4 | 3.4 |
| Axitinib | 5 | 3.2 | 3.2 |
| Natalizumab | 45 | 3.1 | 3.1 |
| Bimekizumab | 5 | 2.9 | 2.9 |
| Peginterferon Beta-1A | 3 | 2.8 | 2.8 |
| Orlistat | 5 | 2.4 | 2.4 |
| Pirfenidone | 7 | 2.1 | 2.1 |